
ODTX Stock Forecast & Price Target
ODTX Analyst Ratings
Bulls say
Odyssey Therapeutics is supported by a first-in-class oral RIPK2 scaffolding inhibitor, OD-001, that targets an upstream innate-immune node to suppress multiple validated UC cytokines at once, a mechanism orthogonal to approved therapies and potentially useful as both monotherapy and combination backbone. Its Phase 2a data are encouraging, with a 2.6-point modified Mayo reduction (p<0.001), 27% clinical remission at 20 mg BID, and no serious adverse events, serious infections, treatment-related discontinuations, or liver-function signals, while remission held up in advanced-therapy-experienced patients at 25%. Financially, the company ended 2Q26 with $433M in cash and equivalents, and the model assumes roughly $2.95B U.S. and $1.6B ex-U.S. peak sales for OD-001, plus upside from OD-002, OD-003, and the rest of the pipeline.
Bears say
Odyssey Therapeutics is viewed negatively because its lead asset OD-001 is only in Phase 2a/b, leaving substantial clinical-development risk that could easily delay or derail the program if primary endpoints are missed or efficacy proves lower than expected. The company also faces meaningful regulatory and commercial uncertainty, with FDA discussions still needed, a crowded autoimmune and inflammatory disease landscape, and the possibility that combination or novel-target approaches fail to outperform existing therapies. Financially, the risk profile is amplified by an estimated ~48M shares post-IPO, expected GAAP EPS of ($1.13) in 3Q26 and ($6.13) in 2026, and a projected GAAP net loss and operating cash flow burn until 2034, implying continued dependence on external financing and added volatility around the early November lock-up expiration.
This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Odyssey Therapeutics Inc (ODTX) Forecast
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares